Solomon Moshkevich Sells 2,206 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Key Points

• Insider Solomon Moshkevich sold 2,206 shares of Natera stock for a total of $308,420.86, reducing their ownership by 1.72% to 126,059 shares.
• Natera recently reported a 36.5% increase in revenue year-over-year, with earnings per share (EPS) reaching ($0.50), beating analysts' expectations.
• Despite mixed ratings from analysts, Natera currently holds a consensus rating of "Moderate Buy" with a target price of $183.76.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 2,206 shares of Natera stock in a transaction on Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $308,420.86. Following the completion of the transaction, the insider owned 126,059 shares in the company, valued at $17,624,308.79. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $40,533.39.
• On Tuesday, May 27th, Solomon Moshkevich sold 1,649 shares of Natera stock. The stock was sold at an average price of $156.85, for a total value of $258,645.65.
• On Tuesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.77, for a total transaction of $500,310.00.
• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $157.07, for a total value of $471,210.00.
• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $150.12, for a total transaction of $450,360.00.

Natera Stock Performance

NASDAQ:NTRA traded up $0.92 on Friday, reaching $134.58. The company's stock had a trading volume of 1,165,817 shares, compared to its average volume of 1,493,227. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The firm has a market cap of $18.38 billion, a PE ratio of -91.55 and a beta of 1.73. The business's 50-day moving average price is $157.54 and its two-hundred day moving average price is $156.09.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same period in the previous year, the firm earned ($0.56) earnings per share. The company's revenue was up 36.5% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. LPL Financial LLC raised its stake in Natera by 33.7% in the fourth quarter. LPL Financial LLC now owns 80,332 shares of the medical research company's stock valued at $12,717,000 after purchasing an additional 20,260 shares in the last quarter. Prudential Financial Inc. raised its holdings in Natera by 18.2% during the 4th quarter. Prudential Financial Inc. now owns 18,370 shares of the medical research company's stock worth $2,683,000 after purchasing an additional 2,824 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Natera by 67.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 43,626 shares of the medical research company's stock worth $7,312,000 after purchasing an additional 17,496 shares during the period. Blair William & Co. IL acquired a new position in shares of Natera in the 4th quarter worth approximately $426,000. Finally, DnB Asset Management AS bought a new stake in shares of Natera in the 4th quarter valued at $235,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on NTRA. Piper Sandler raised their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Evercore ISI began coverage on Natera in a research report on Monday. They issued an "outperform" rating and a $170.00 price target for the company. Barclays raised their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Finally, UBS Group upped their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus price target of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.